Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;35(12):3597-3604.
doi: 10.1007/s11606-020-06180-8. Epub 2020 Sep 28.

Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin

Marie Bradley  1 , Emily C Welch  2 , Efe Eworuke  3 , David J Graham  3 , Rongmei Zhang  4 , Ting-Ying Huang  2
Affiliations

Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin

Marie Bradley et al. J Gen Intern Med. 2020 Dec.

Abstract

Background: A previous FDA study reported a favorable benefit risk for apixaban compared with warfarin for stroke prevention in older non-valvular atrial fibrillation (NVAF) patients (≥ 65 years). However, it remains unclear whether this favorable benefit risk persists in other populations including younger users. We examined if a similar benefit risk was observed in the Sentinel System and if it varied by age group.

Objective: To examine the risk of ischemic stroke, gastrointestinal (GI) bleeding, and intracranial hemorrhage (ICH) in apixaban users compared with warfarin users in Sentinel Distributed Database (SDD).

Design and participants: A retrospective new user cohort study was conducted among patients, 21 years and older initiating apixaban and warfarin for NVAF, between December 28, 2012, and June 30, 2018, in the SDD.

Main measures: Cox proportional hazard regression was used to estimate the hazard ratios (HR) and 95% confidence intervals (95% CI) for each outcome (ischemic stroke, GI bleeding, and ICH) in propensity score matched apixaban users compared with the warfarin users. Subgroup analyses by age (21-64, 65-74, and 75+ years) were conducted.

Key results: After matching, 55.3% and 58.4% (n = 55,038) of the apixaban and warfarin users were included in the main analysis. GI bleeding was the most common outcome. The HR (95% CI) for GI bleeding, ICH, and ischemic stroke in apixaban users compared with warfarin users were 0.57 (0.50-0.66), 0.53 (0.40-0.70), and 0.56 (0.45-0.71) respectively. The reduced risk of these outcomes in apixaban compared with warfarin users persisted across age groups.

Conclusion: In NVAF patients of all ages initiating either apixaban or warfarin for stroke prevention in the Sentinel System, apixaban was associated with a decreased risk of GI bleeding, ICH, and ischemic stroke compared with warfarin. Among patients less than 65 years of age, apixaban use was associated with a decreased risk of GI bleeding and ischemic stroke.

Keywords: Sentinel System; apixaban; bleeding; non-valvular atrial fibrillation; stroke; warfarin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have a conflict of interest.

Figures

Figure 1
Figure 1
Forest plot showing estimates for each outcome overall and by age group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019–26. doi: 10.1056/NEJMoa022913. - DOI - PubMed
    1. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313(19):1950–62. doi: 10.1001/jama.2015.4369. - DOI - PubMed
    1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469–73. doi: 10.1001/archinte.1995.00430050045005. - DOI - PubMed
    1. Prevention CfDCa . Atrial fibrillation fact sheet. Atlanta: Centers for Disease Control and Prevention; 2017.
    1. Moss JD, Cifu AS, Guidelines AATFoP Management of anticoagulation in patients with atrial fibrillation. JAMA. 2015;314(3):291–2. doi: 10.1001/jama.2015.3088. - DOI - PubMed

Publication types